Skip to content
Luna Metabolic
Menu

Women's-health guide

GLP-1 Medicines, Your Cycle, and Contraception

Appetite, the menstrual cycle, birth control absorption and pregnancy — the women's-specific questions worth raising before you start a GLP-1.

By The Luna Editorial Team, Women's Metabolic Health Desk
On this page

Our pick for women

Grade A

CoreAge Rx

93/100

The most reliable on-ramp for women: nationwide access to both molecules at one flat, no-surprise price — including tirzepatide, the option many women with insulin resistance want.

Check availability
Semaglutide
$149/mo
Tirzepatide
$349/mo
Full review →Ad disclosure — we may earn a commission.

Also worth a look

Strut Health

Grade B

One of the few programs with a women's weight-loss line of its own, and the widest set of routes we track — injectable or sublingual, semaglutide or tirzepatide, each with its price on the page.

FDA warning letterFebruary 2026Read it ↗Visit Strut Health

Birth control: a caution worth taking seriously

This is the single women's-health point most often missed. Tirzepatide can reduce the effectiveness of oral contraceptives, and its labeling advises women using the pill to switch to a non-oral method or add a barrier method around starting and dose increases2. The mechanism — slowed gastric emptying affecting absorption — is exactly why it matters most when your dose is changing. If you rely on the pill, raise this with your provider before your first injection, not after. Our full guide to GLP-1s and birth control breaks down why tirzepatide and semaglutide differ here and which methods are unaffected.

Weight loss, ovulation and unplanned pregnancy

Losing weight and improving insulin sensitivity can restore more regular ovulation, particularly in women with PCOS. That is usually welcome, but it also means fertility can increase unexpectedly on treatment4. Because GLP-1 medicines are not appropriate during pregnancy, reliable contraception during treatment — and a plan to stop well before trying to conceive — is part of using them responsibly1.

Appetite, cycle symptoms and side effects

Many women notice that appetite and cravings already fluctuate across the menstrual cycle; GLP-1 medicines act on the same appetite pathways, and some women report that nausea or fullness feels more pronounced at certain points in their cycle. There is limited formal research here, so it is best treated as something to track and discuss rather than a fixed rule. The larger trials establish the overall efficacy and side-effect profile of these drugs across mixed populations3. Headaches that cluster around your cycle are worth separating from a different, less commonly discussed pattern: migraine and a related condition, idiopathic intracranial hypertension, both skew heavily female and both show real early evidence of responding to GLP-1 treatment directly, not just through weight loss — covered in our guide to GLP-1, migraine and intracranial hypertension in women.

Bring these questions to a provider

A provider that understands women's health should be able to talk through contraception, pregnancy planning, and how your cycle interacts with dosing — not just hand over a prescription. That kind of oversight is what our ranking rewards; see the Luna Fit Score methodology and our provider reviews. This guide is educational only and is not medical advice.

Frequently asked questions

Can a GLP-1 medicine make my birth control pill fail?

Tirzepatide's labeling warns it can reduce oral contraceptive effectiveness, especially around starting and dose increases, and advises a non-oral or barrier method. Discuss your contraception with your provider before starting.

Do I need to stop before trying to get pregnant?

Yes. GLP-1 medicines are not used in pregnancy, and guidance advises stopping well before a planned pregnancy. Because treatment can also restore ovulation, plan contraception and timing with your clinician.

References

  1. U.S. Food and Drug Administration (2023). Wegovy (semaglutide) injection — prescribing information. FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
  2. U.S. Food and Drug Administration (2022). Mounjaro (tirzepatide) injection — prescribing information (oral contraceptive caution). FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf
  3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2206038
  4. American College of Obstetricians and Gynecologists (2023). Polycystic Ovary Syndrome (PCOS): patient FAQ. ACOG. https://www.acog.org/womens-health/faqs/polycystic-ovary-syndrome-pcos

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

Keep exploring